Scinai Immunotherapeutics Ltd. · NASDAQ:SCNI
Scinai Immunotherapeutics — BiondVax Pharmaceuticals — Investor Presentation (January 2022)
17 slides from Scinai Immunotherapeutics's investor presentation, Jan 11, 2022
Slide 1: BiondVax Pharmaceuticals Ltd.
Biond Vax Pharmaceuticals Ltd. NASDAQ: BVXV | January 2022
Slide 2: Forward-looking statements
2 This communication contains forward - looking statements within the meaning of the Private Litigation Reform Act of 1995 . Words such as “expect,” “believe,” “intend,” “plan,” “continue,” “may,” “will,” “anticipate,” and similar expressions are intended to identify forward - looking statements . A
Slide 3: Developing innovative NanoAb COVID-19 therapy: significant potential for value creation
• New strategic collaboration with world - renowned Max Planck Institute & University Medical Center Göttingen (UMG) scientists affords access to unique biophysics know - how and IP to generate NanoAbs that exhibit significant competitive advantages • BiondVax to lead development and commercializati
Slide 4: Collaboration with Max Planck
4 COLLABORATION WITH MAX PLANCK Capabilities to develop significant clinical and commercial advantages MA X PLANC K ( 1 ) • World - class science & access to leading scientists • NanoAb platform for development of promising potent therapeutics • Patents covering NanoAbs & their manufacturing BIONDVA
Slide 5: The science of nanosized antibodies (NanoAb)
5 * Nanobody is trademarked by ABLYNX N.V., a wholly owned subsidiary of Sanofi. BiondVax has no affiliation with and is not endorsed by Sanofi. THE SCIENCE OF NANOSIZED ANTIBODIES (NANOAB ) H U M A N A N T I B O D Y A L P A C A - D E R I V E D NANOAB Alpaca - derived nanosized VHH - Antibodies (Nan
Slide 6: NanoAb value proposition
6 N ANO A B VALUE PROPOSITION Multiple crucial advantages compared to monoclonal antibodies (mAbs) & oral therapies CLINICAL BENEFITS CONVENIENT & FLEXIBLE • Hyperthermostability = longer shelf life, easier storage & distribution • Multiple, easier routes of administration • Faster, lower - cost pro
Slide 7: NanoAb candidate has a strong competitive edge
7 COVID - 19 NANOAB CANDIDATE HAS A STRONG COMPETITIVE EDGE 1 . In - vitro data shows neutralization of all COVID variants of concern including Delta, and based on in - silico studies, Omicron | 2. EMBO J (2021) 40: e107985 https://doi.org/10.15252/embj.2021107985 . | P R O F . D R . D I R K GÖRLICH
Slide 8: Creating an innovative NanoAb pipeline
1. Based on laboratory research at Max Planck Institute for Biophysical Chemistry (MPG) and University Medicine Göttingen (UMG); | 8 2. Term sheets signed October 19, 2021; Final agreements anticipated by end of January 2022 CREATING AN INNOVATIVE NANOAB PIPELINE Extending from a promising COVID - 1
Slide 9: Market continues to grow
9 COVID - 19 MARKET CONTINUES TO GROW 1.5M cases 1M 500K I niti a l w a v es Apr. 2020 J ul. Oct. Jan 2021 A pr J ul Oct Jan 2022 1 . New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMp2118468 . | 2. WHO “ SARS - CoV - 2 is unlikely to be eliminated, let alone eradicated ; i
Slide 10: Market potential & timeline
€2.6B asthma €10.4B psoriasis €5.0B macular dege n er a t i o n €4.5B psoriatic arthritis MARKET POTENTIAL & TIMELINE I N I T I A L F O C U S 10 * Sources: Datamonitor; Fiercepharma; L.E.K. research and analysis; 2020 $ 1 .6 B + Projected CO V I D - 19 a n t ib o dy market 2022 2023 F U T U R E D E
Slide 11: Market comparators
MARKET COMPARATORS Adagio (ADGI): • Dec 2021: Lead mAb candidate ADG20 found ineffective against Omicron leading to over $5B drop in market cap Vir (VIR) • In partnership with GSK received emergency use authorization for mAb Sotrovimab • $4.5B Market Cap Jan 2022 Pardes (PRDS) • Oral protease inhibi
Slide 12: Top-tier pharma leadership
Top - tier pharma lea d e rs hip Collaboration with Max Planck & UMG GMP biologics m a n u fact ur ing facility Extensive drug development expertise Uniquely positioned to advance nanosized antibody innovation from R&D through commercialization
Slide 13: GMP manufacturing facility
13 GMP MANUFACTURING FACILITY Well - suited for NanoAb development AND production • Equipped to produce recombinant protein products such as NanoAb • Single - use equipment enables: - Adaptable manufacturing processes for entire NanoAb pipeline - Quicker lead times - Faster time - to - market for ne
Slide 14: Experienced leadership
14 EXPERIENCED LEADERSHIP COO Built manufacturing sites for recombinant protein in China and mABs for Novartis Singapore • BSc. Engineering (Afeka Tel Aviv College of Engineering) • MBA (Open University of Israel) • Principal bioprocess engineer • Novartis (Technical Project Manager - Process) Elad
Slide 15: Board brings significant expertise
15 Amir Reichman, MBA CEO NeuroDerm Ltd (Senior Scientist), Novartis Vaccines USA (R&D and Global Supply chain), GSK Vaccines Belgium (Global Supply Chain and Global Engineering) Morris C. Laster, MD Director BioLineRx (CEO, Director), OurCrowd (Partner), Clil Medical (CEO), Vital Spark (CEO), Kitov
Slide 16: Select financials & cap table
16 SELECT FINANCIALS & CAP TABLE • $17.5M cash as of December 31, 2021 • $ 24 M estimated cash requirement to COVID clinical proof - of - concept H2 2023 • €24M European Investment Bank (EIB) non - dilutive co - funding agreement • Government of Israel support CAP TABLE As of Dec. 31, 2021 ADS OUTST
Slide 17: Significant potential for value creation
SIGNIFICANT POTENTIAL FOR VALUE CREATION Targeting massive, validated addressable markets with a pipeline of NanoAbs Strategic collaboration with Max Planck Institute world - leading research organization Lead candidate to treat COVID - 19 has strong competitive edge Well - positioned to bring innov
BiondVax Pharmaceuticals — Investor Presentation (January 2022) on 6ix